Cyllene Therapeutics
PrivateLast Round
Series C
Jul 7, 2026
Total Funding Raised
$93.95M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Cyllene Therapeutics is a biotechnology company that develops non-replicating HSV-1 vector technology for neurological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cyllene Therapeutics Comparables
Compare Cyllene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Replay | 76% | |
| Sumitomo Pharma Co., Ltd. | 74% | |
| Guangzhou Yinming Biomedical Technology | 64% |
Cyllene Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 7, 2026 | ||||
| Series B | Feb 20, 2025 | ||||
| Series A Extension | Jul 13, 2023 | ||||
| Series A | Mar 1, 2021 | ||||
| Seed | May 1, 2019 |
Key People
Founding team and executive leadership
Cyllene Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SCI Ventures | Series B |
| GordonMD Global Investments | Series C |
| Andera Partners | Series C, Series B |
| M Ventures | Series C |
| Bpifrance | Series B, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 20% QoQ, from 25 to 30 employees.
- Jul 7, 2026
$38M round led by GordonMD Global Investments and M Ventures.
Recent news
Latest coverage and updates
- receives_financingJul 7, 2026
Eg427 received financing of $37.7M in Series C on Jul 7th '26.
- is_developingJun 24, 2026
Eg427 is developing targeted gene therapy for bladder dysfunction.
Cyllene Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cyllene Therapeutics's valuation, stock price, and market status.
Is EG 427 a public or private company?
EG 427 is a private company.
What is the current stock price of EG 427?
EG 427 is a private company with no public stock price. No recent secondary market data is available.
How much is EG 427 worth (valuation)?
Valuation information for EG 427 is not publicly available.
Can I buy EG 427 stock?
EG 427 shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was EG 427's last funding round?
EG 427's most recent funding round was Series B on February 20, 2025.
Who are the main investors in EG 427?
Key investors in EG 427 include Andera Partners, Bpifrance.
Will EG 427 IPO soon?
No public IPO plans have been announced for EG 427.
How can I track EG 427 secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EG 427's secondary market activity and sign up for updates.